News

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...
Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...
Japanese authorities are putting Eisai (TSE: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...
TOKYO – Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co.
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...
Eisai Pharma to establish Global Capability Center in Visakhapatnam, expanding digital innovation presence in India.
Eisai officials said the new study recruited 1,795 people with earlier Alzheimer's disease and amyloid beta in the brain. Participants received either a 10 mg per kilogram dose every two weeks ...
NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...
Eisai employs 1,680 people in the U.S. and more than 10,000 people around the world. At its Nutley headquarters, the company has almost 700 employees.
Access Eisai stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.
Eisai Co., Ltd. and Biogen Inc. announced that the European Commission has granted marketing authorization for lecanemab, marketed as Leqembi®, making it the first therapy in the EU to target an ...
Eisai shares opened 0.2% lower on June 19, the day NICE announced its final decision. The US stock market, where Eli Lilly is listed, had not yet opened at the time of writing.